Sort by
Refine Your Search
-
Listed
-
Country
-
Field
-
Biologics Screening Core within the Department of Host Microbe Interactions at St. Jude seeks a skilled and highly motivated candidate with experience in Antibody Discovery . This is a unique opportunity to
-
Sorbonne Université SIS (Sciences, Ingénierie, Santé) | Paris 15, le de France | France | 11 days ago
compréhension des processus physiologiques au niveau moléculaire et pour l'amélioration des approaches théoriques pour le traitement des maladies. Le groupe de recherche hôte (https://sites.google.com/site
-
cytometry, and antibody production, as well as NBIS (National Bioinformatics Infrastructure Sweden). The department hosts a unit within Display and Selection Technologies , which is part of the national
-
I position is available in the RSP Lab led by Dr. Sklavenitis Pistofidis. The RSP Lab (https://rsplab.org ) leverages advanced multi-omic technologies, coupled with experimental perturbations and
-
genome sequencing fields, and subsequent performance of assays. Work schedule: 100% FTE Monday – Friday Day shift What you’ll contribute: Conduct neutralizing antibody assays, viral culture isolation, and
-
procedures including HLA typing by rSSO and next generation sequencing methods, Luminex based HLA Antibody identification, and donor/recipient flow cytometric cross-matching. They are expected to keep all
-
. The posted UC academic salary scales set the minimum pay determined by rank and/or step at appointment. See the following table for the salary scale for this position (Salary Scale Represented: https
-
(SHM) is a key process in diversification of antibodies. This process is initiated by cytosine deamination by the activation-induced cytidine deaminase (AID) and completed by error-prone processing
-
are not curative. To enhance their efficacy, BTK/PI3K inhibitors are commonly combined with anti-CD20 monoclonal antibodies. We suppose that BTK inhibitors (BTKi) disrupt the regulation of CD20
-
, including the use of tumor vaccines, cellular therapy for cancer, antibody-based treatments, and novel forms of chemotherapy and hormonal therapy. Our division is deeply committed to maintaining its position